Rapid Responses to:

NEWS ROUNDUP: Lynn Eaton Regulator restricts use of SSRIs in children BMJ 2005; 330: 984-a [Full text]

Rapid Responses: Submit a response to this article

Rapid Responses published:

Correction

Suyash Prasad   (5 May 2005)

Correction 5 May 2005
Suyash Prasad, Paediatrician and Clinical Research Physician Eli Lilly and Co Ltd, Lilly House, Priestley Rd, Basingstoke, Hampshire, RG24 9NL Send response to journal: Re: Correction	We welcome the BMJ’s recognition that reporting ongoing safety concerns regarding medications in children, especially the use of unlicensed medications in this group, is a priority, however we feel it important to address some inaccuracies in the article, as this may have a detrimental effect on clinician decision-making and patient compliance. Atomoxetine does not increase the risk of suicide related behaviours. The article suggests that atomoxetine is included in a group of medicines that demonstrate a higher incidence of suicidality. This statement is incorrect with regard to atomoxetine as recognised in question 4 of the European Medicines Agency's (EMEA) review of antidepressants in children and adolescents, reported in their press release of 25th April 2005 (http://www.emea.eu.int/pdfs/human/press/pr/12891805en.pdf). It is correct that atomoxetine has a potentially increased risk of hostility and emotional lability. The article suggests that atomoxetine is an antidepressant; this is incorrect. Atomoxetine demonstrates no antidepressant activity as is recognised by the EMEA Q&A document. It has undergone a comprehensive clinical trial progam in children and adolescents that has established its efficacy and safety in a paediatric population. Atomoxetine is licensed as a treatment for attention deficit hyperactivity disorder (ADHD)in children and adolescents. The article classifies atomoxetine as an SSRI or SNRI; this is incorrect. Atomoxetine has activity only at the pre-synaptic norepinephrine (noradrenaline) transporter and is in keeping with the description of the pharmacological action of atomoxetine as described in its Summary of Product Characteristics It is important to clarify these points, specifically noting that atomoxetine is licensed only for the treatment of ADHD, and shows no increase in the rate of suicide related behaviours: these are important amendments to make as the BMJ website is accessed by many patients and carers, and inaccurate information may lead to inappropriate and premature withdrawal of the medication with potentially detrimental effects on patient care. Competing interests: Dr Suyash Prasad is a full time employee of Eli Lilly and Co